Abstract
Aurora kinase A is involved in multiple mitotic events in cell cycle and has been identified as a major regulator of centrosome function in mitosis. Aurora A has been found to be over-expressed in many tumor types including breast, lung, colon, ovarian, pancreatic and glial cells. Thus, inhibition of aurora A can be a potential target in oncology. A five-point pharmacophore was generated using PHASE for a set of aurora A inhibitors reported in literature. The generated pharmacophore yielded statistically significant 3D-QSAR model, with a correlation coefficient r 2 of 0.936 and q 2 of 0.703. The pharmacophore indicated that presence of two aromatic ring features (R), two acceptor features (A) and one donor feature (D) is necessary for potent inhibitory activity. The database screening was done initially by use of pharmacophore followed by an interaction-based selection using docking. Twelve hits with satisfactory pharmacokinetic properties have been identified.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Belanger DB, Curran PJ et al (2010) Discovery of imidazo [1, 2-a] pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett 20(17):5170–5174
Blanchard S, William AD et al (2010) Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors. Bioorg Med Chem Lett 20(8):2443–2447
Bouloc N, Large JM et al (2010) Structure-based design of imidazo [1, 2-a] pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells. Bioorg Med Chem Lett 20(20):5988–5993
Brazidec J-YL, Pasis A et al (2012) Structure-based design of 2, 6, 7-trisubstituted-7H-pyrrolo [2, 3-d] pyrimidines as Aurora kinases inhibitors. Bioorg Med Chem Lett 22(12):4033–4037
Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4(11):842–854
Carvajal RD, Tse A et al (2006) Aurora kinases: new targets for cancer therapy. Clin Cancer Res 12(23):6869–6875
Deng XQ, Wang HY et al (2008) Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors. Chem Biol Drug Des 71(6):533–539
Fancelli D, Moll J Jr et al (2006) 1, 4, 5, 6-tetrahydropyrrolo [3, 4-c] pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 49(24):7247–7251
Gergely F (2008) Mitosis: Cdh1 clears the way for anaphase spindle assembly. Curr Biol 18(21):R1009–R1012
Heron NM, Anderson M et al (2006) SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg Med Chem Lett 16(5):1320–1323
Hirota T, Kunitoku N et al (2003) Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114(5):585–598
Katayama H, Sen S (2010) Aurora kinase inhibitors as anticancer molecules. BBA-gene regulatory mechanisms 1799(10–12):829–839
Katayama H, Sasai K et al (2003) Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36(1):55–62
Keen N, Taylor S (2004) Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4(12):927–936
Kimura M, Matsuda Y et al (1999) Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem 274(11):7334–7340
Mao J-H, Wu D et al (2007) Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell 11(2):161–173
Marumoto T, Zhang D et al (2005) Aurora-A-a guardian of poles. Nat Rev Cancer 5(1):42–50
McClellan WJ, Dai Y et al (2011) Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases. Bioorg Med Chem Lett 21(18):5620–5624
Morshed MN, Cho YS et al (2011) Computational approach to the identification of novel Aurora-A inhibitors. Bioorgan Med Chem 19(2):907–916
Oslob JD, Romanowski MJ et al (2008) Discovery of a potent and selective Aurora kinase inhibitor. Bioorg Med Chem Lett 18(17):4880–4884
Pan W, Liu H et al (2005) Pyrimido-oxazepine as a versatile template for the development of inhibitors of specific kinases. Bioorg Med Chem Lett 15(24):5474–5477
Singh D, Karthikeyan M et al (2011) Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors. J Mol Graph Model 30:186–197
Talele TT, McLaughlin ML (2008) Molecular docking/dynamics studies of Aurora A kinase inhibitors. J Mol Graph Model 26(8):1213–1222
Vader G, Lens S (2008) The Aurora kinase family in cell division and cancer. BBA-Rev Cancer 1786(1):60–72
Vianello P (2007) Aminopyridines: selective AuroraA inhibitors. Expert Opin Ther Pat 17(2):255–261
Wang XJ, Chen YD et al (2007) The pharmacophore hypothesis of novel inhibitors for Aurora A kinase. Chin J Chem 25(12):1911–1918
Wiese C, O’Brien LL (2006) What’s so Bor (a) ing about Aurora-A activation? Dev Cell 11(2):133–134
Yan A, Wang L et al (2011) Aurora-A kinase inhibitor scaffolds and binding modes. Drug Discov Today 16(5):260–269
Acknowledgments
Department of Biotechnology, Government of India for sanction of Research Grant (F. No. BT/PR14373/Med/30/530/2010), and Schrödinger for extending the licence of Glide.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Joshi, A.J., Gadhwal, M.K. & Joshi, U.J. A combined approach based on 3D pharmacophore and docking for identification of new aurora A kinase inhibitors. Med Chem Res 23, 1414–1436 (2014). https://doi.org/10.1007/s00044-013-0747-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-013-0747-5